Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.
Multiple myeloma (MM) is the second most prevalent hematologic malignancy which remains uncurable. Numerous drugs have been discovered to inhibit MM cells. Indisulam, an aryl sulfonamide, has a potent anti-myeloma activity in vitro and in vivo. This study aims to explore the new mechanism of indisul...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0299019&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839607474926125056 |
|---|---|
| author | Chengyu Wu Chao Wu Jia Liu Mingyuan Jia Xinyi Zeng Ze Fu Ziqi He Wenbin Xu Hua Yan |
| author_facet | Chengyu Wu Chao Wu Jia Liu Mingyuan Jia Xinyi Zeng Ze Fu Ziqi He Wenbin Xu Hua Yan |
| author_sort | Chengyu Wu |
| collection | DOAJ |
| description | Multiple myeloma (MM) is the second most prevalent hematologic malignancy which remains uncurable. Numerous drugs have been discovered to inhibit MM cells. Indisulam, an aryl sulfonamide, has a potent anti-myeloma activity in vitro and in vivo. This study aims to explore the new mechanism of indisulam and investigate its potential use in combination with melphalan. We examined DNA damage in MM cells through various methods such as western blotting (WB), immunofluorescence, and comet assay. We also identified the role of topoisomerase IIα (TOP2A) using bioinformatic analyses. The impact of indisulam on the RNA and protein levels of TOP2A was investigated through qPCR and WB. Cell proliferation and apoptosis were assessed using CCK-8 assays, Annexin V/PI assays and WB. We predicted the synergistic effect of the combination treatment based on calculations performed on a website, and further explored the effect of indisulam in combination with melphalan on MM cell lines and xenografts. RNA sequencing data and basic experiments indicated that indisulam caused DNA damage and inhibited TOP2A expression by decreasing transcription and promoting degradation via the proteasome pathway. Functional experiments revealed that silencing TOP2A inhibited cell proliferation and induced apoptosis and DNA damage. Finally, Indisulam/melphalan combination treatment demonstrated a strong synergistic anti-tumor effect compared to single-agent treatments in vitro and in vivo. These findings suggest that combination therapies incorporating indisulam and melphalan have the potential to enhance treatment outcomes for MM. |
| format | Article |
| id | doaj-art-a0d3aab31c894be4a7d400a2f43ae9ab |
| institution | Matheson Library |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-a0d3aab31c894be4a7d400a2f43ae9ab2025-08-01T05:31:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01194e029901910.1371/journal.pone.0299019Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.Chengyu WuChao WuJia LiuMingyuan JiaXinyi ZengZe FuZiqi HeWenbin XuHua YanMultiple myeloma (MM) is the second most prevalent hematologic malignancy which remains uncurable. Numerous drugs have been discovered to inhibit MM cells. Indisulam, an aryl sulfonamide, has a potent anti-myeloma activity in vitro and in vivo. This study aims to explore the new mechanism of indisulam and investigate its potential use in combination with melphalan. We examined DNA damage in MM cells through various methods such as western blotting (WB), immunofluorescence, and comet assay. We also identified the role of topoisomerase IIα (TOP2A) using bioinformatic analyses. The impact of indisulam on the RNA and protein levels of TOP2A was investigated through qPCR and WB. Cell proliferation and apoptosis were assessed using CCK-8 assays, Annexin V/PI assays and WB. We predicted the synergistic effect of the combination treatment based on calculations performed on a website, and further explored the effect of indisulam in combination with melphalan on MM cell lines and xenografts. RNA sequencing data and basic experiments indicated that indisulam caused DNA damage and inhibited TOP2A expression by decreasing transcription and promoting degradation via the proteasome pathway. Functional experiments revealed that silencing TOP2A inhibited cell proliferation and induced apoptosis and DNA damage. Finally, Indisulam/melphalan combination treatment demonstrated a strong synergistic anti-tumor effect compared to single-agent treatments in vitro and in vivo. These findings suggest that combination therapies incorporating indisulam and melphalan have the potential to enhance treatment outcomes for MM.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0299019&type=printable |
| spellingShingle | Chengyu Wu Chao Wu Jia Liu Mingyuan Jia Xinyi Zeng Ze Fu Ziqi He Wenbin Xu Hua Yan Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. PLoS ONE |
| title | Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. |
| title_full | Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. |
| title_fullStr | Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. |
| title_full_unstemmed | Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. |
| title_short | Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. |
| title_sort | indisulam synergizes with melphalan to inhibit multiple myeloma malignancy via targeting top2a |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0299019&type=printable |
| work_keys_str_mv | AT chengyuwu indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT chaowu indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT jialiu indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT mingyuanjia indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT xinyizeng indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT zefu indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT ziqihe indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT wenbinxu indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a AT huayan indisulamsynergizeswithmelphalantoinhibitmultiplemyelomamalignancyviatargetingtop2a |